CPA
STOK icon

Capital Performance Advisors’s Stoke Therapeutics STOK Stock Holding History

Capital Performance Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32
Closed -$393 – 2367
2024
Q3 		$393 Buy
+32
New +$453 ﹤0.01% 2357

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Capital Performance Advisors's STOK Position: Q4 2024 in Review

Capital Performance Advisors sold out of Stoke Therapeutics (STOK) in Q4 2024, closing a stake of 32 shares — an estimated $393 sold.

Capital Performance Advisors first reported a position in STOK in Q3 2024 and held it in 1 quarter. The position peaked at $393 in Q3 2024. 130 funds tracked by Wall St. Rank hold STOK as of Q4 2024.

  • Capital Performance Advisors reported no remaining Stoke Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 32 Stoke Therapeutics shares in Q4 2024, an estimated $393.
  • Capital Performance Advisors first reported a position in Stoke Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Stoke Therapeutics position peaked at $393 in Q3 2024.
  • 130 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.